A carregar...

TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathways

The death receptor (DR) ligand TRAIL is being evaluated in clinical trials as an anti-cancer agent; however, many studies have found that TRAIL also enhances tumor progression by activating the NF-κB pathway in apoptosis-resistant cells. Although RIP1, cFLIP and caspase-8 have been implicated in TRA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Signal
Main Authors: Zhang, Laiqun, Dittmer, Martin R, Blackwell, Ken, Workman, Lauren M., Hostager, Bruce, Habelhah, Hasem
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4276503/
https://ncbi.nlm.nih.gov/pubmed/25446254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cellsig.2014.11.014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!